Seattle, WA April 3, 2024 – Pluristyx, a leading provider of tools, technologies, and services for cellular therapies, is pleased to announce the release of its proprietary cryopreservation medium solution, PluriFreeze™. Immediately available in a Research Use Only (RUO) formulation with a Good Manufacturing Practice (GMP) version on the horizon, PluriFreeze™ constitutes a further addition […]
Newark, New Jersey March 7, 2024 BioCentriq, Inc., a global cell therapy Contract Development and Manufacturing Organization (CDMO), is proud to announce a significant enhancement to its partnership with Pluristyx Inc., an early stage, privately held biotechnology company specializing in Induced Pluripotent Stem Cell (iPSC) products. Through BioCentriq’s process development services, their strategic collaboration now
The addition of ES cells and iPSCs will enhance Charles River’s portfolio of powerful research tools supporting acceleration of therapeutic development. WILMINGTON, Mass. – February 20, 2024 – Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into an agreement with Pluristyx Inc., a leading provider of tools, technologies, and services for
Pluristyx, Inc., with expertise in gene-edited induced pluripotent stem cells (iPSCs) and National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines today, today announced a collaboration agreement to streamline the transition of promising iPSC-derived therapies from the benchtop to the bedside. The partnership provides a pathway to transition early-stage
Chimeric antigen receptor (CAR) T-cell therapies are a novel class of targeted and personalized immunotherapy which have shown remarkable success to date in treating certain hematological malignancies, including certain types of leukemia and lymphoma. There are currently six commercially available CAR T-Cell therapies: Abecma, Breyanzi, Kymriah, Tecartus, Yescarta, and Carvykti (Ghosh, 2023). There are a
FailSafe®: Engineered safety for tomorrow’s cell therapies Read More »
SEATTLE, WA - December 21, 2023 - Pluristyx, a leading provider of tools, technologies and services for the development of cell therapies, has today announced the closing of a major fundraising round led by BroadOak Capital Partners. The oversubscribed funding round also featured participation from existing investors and key opinion leaders across the life sciences
Pluristyx Announces Major New Funding Round to Bolster Expansion Plans Read More »
Introduction to Cryopreservation Cryopreservation describes the controlled process of freezing biological material at extremely low temperatures in order to discontinue biochemical reactions, including those associated with cell death and DNA damage, to allow long-term storage and/or transport. Given recent medical advances in cell-based therapies, the importance of cryopreservation continues to increase based on the necessity
Harding J, Vinterstein-Nagy K, Nagy A. (2020) Cell Stem Cell. 2020. Aug 6, 27(2): 198-9. Letter re: Gonzalez BJ et al, (Cell Stem Cell 26:307-308, March 5, 2020). PMID: 32763181
Universal Stem Cells: making the unsafe safe. Read More »
Lanza R, Russell D, Nagy A. (2019) Nature Reviews | Immunology. 2019. Aug 15. doi: 10.1038/s41577-019-0200-1 [Epub head of print]. PMID: 31417198
Engineering universal cells that evade immune detection. Read More »
Harding, J., Vintersten-Nagy, K., Shutova, M., Yang, H., Tang, J., Massumi, M., Izadifar, M., Izadifar, Z., Zhang, P., Li, C., et al. and Nagy, A. (2019). BioRxiv, 2019, doi: https://doi.org/10.1101/716571
